- Adjuvant chemoradiotherapy (CRT) is associated with reduced recurrence and better survival in lymph node-positive gallbladder cancer.
- No benefit observed in node-negative patients.
Why this matters
- Previous studies have combined gallbladder and extra- and intrahepatic bile duct cancer and patients undergoing surgery with noncurative intent.
- Retrospective analysis of patients with gallbladder cancer who underwent resection with curative intent (n=151).
- Funding: National Cancer Center.
- 64.9% received adjuvant therapy (25.8% chemotherapy, 39.1% CRT) and 35.1% received no adjuvant therapy.
- In T2-3N0M0 stage disease, adjuvant therapy had no effect on 5-year locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), or OS.
- In patients with T2-3N1-2M0 disease, adjuvant CRT was associated with better outcomes than no adjuvant therapy or chemotherapy:
- Locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively; P<.001>
- Distant recurrence (42.8%, 73.9%, and 66.7%, respectively; P=.044).
- LRFS (82.1%, 19.0%, and 26.8%; P<.05>
- RFS (53.3%, 11.6%, and 16.7%; P<.05>
- OS (64.0%, 4.3%, and 22.7%; P<.05>
- Retrospective analysis.
- Single institution.
- Korean population.